Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1605 (LINC01605) is a long non-coding RNA located on chromosome 8, known to play several roles in cancer biology and the regulation of osteogenic differentiation[1][5][3]. It has been implicated in promoting proliferation, migration, and invasion in various cancer cell types by acting as a competing endogenous RNA (ceRNA) that modulates the activity of specific microRNAs such as miR-496-3p and miR-3960, consequently influencing the expression of genes like SOX11[3][5]. LINC01605 has also been described as an osteogenic differentiation inhibitory regulator, blocking the differentiation of mesenchymal stem cells into osteoblasts, thereby potentially influencing bone health[1]. High expression or dysregulation of LINC01605 has been reported as a potential diagnostic or prognostic biomarker for certain cancers, including colorectal cancer and laryngeal squamous cell carcinoma[1][5][3]. There are currently no approved drugs that target LINC01605 directly, and its modulation presents significant therapeutic challenges due to the broad, pleiotropic effects typical of lncRNAs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1605 (LINC01605).